Compositions for inhibiting replication of a virus in a subject (e.g., a human patient) infected with the virus or at risk of being infected with the virus include a therapeutically effective amount of SRSF1 protein, a portion of a SRSF1 protein, or a nucleic acid encoding the SRSF1 protein or a portion thereof, and a pharmaceutically acceptable carrier. Methods of using these compositions, and kits including these compositions, are also described herein. These compositions, kits and methods provide novel therapies for AIDS based on the delivery of SRSF1, single protein domains (portions) derived from SRSF1, and compounds mimicking the activity of such domains.
